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The mechanisms that control the emergence of differ-
ent anterior pituitary cells from a common stem cell
population are largely unknown. The immortalized
GHFT cells derived from targeted expression of SV40 T
antigen to mouse pituitary display characteristics of
somatolactotropic progenitors in that they express the
transcription factor GHF-1 (Pit-1) but not growth hor-
mone (GH) or prolactin (PRL). We searched for factors
capable of inducing lactotropic differentiation of GHFT
cells. PRL gene expression was not observed in cells
subjected to a variety of stimuli, which induce PRL gene
expression in mature lactotropes. Only fibroblast
growth factor-2 (FGF-2) was able to initiate the tran-
scription, synthesis, and release of PRL in GHFT cells.
However, induction of PRL expression was incomplete
in FGF-2-treated cells, suggesting that additional fac-
tors are necessary to attain high levels of PRL transcrip-
tion in fully differentiated lactotropes. We also show
that the FGF-2 response element is located in the prox-
imal PRL promoter. Stimulation of PRL expression by
FGF-2 requires endogenous Ets factors and these factors
as well as GHF-1 are expressed at low levels in the com-
mitted precursor, suggesting that these low levels are
limiting for full PRL expression. Moreover, FGF-2 effect
on lactotrope differentiation is mediated, at least par-
tially, by stimulation of the Ras-signaling pathway. Our
results suggest that, indeed, GHFT cells represent a
valid model for studying lactotropic differentiation and
that FGF-2 could play a key role both in initiating
lactotrope differentiation and maintaining PRL
expression.
The anterior pituitary gland represents an excellent model
system for studying selective gene activation. During embry-
onic development, different types of hormone producing cells
that are highly specialized and synthesize distinct peptide hor-
mones are sequentially derived from a common progenitor cell
population within the anterior pituitary anlagen, Rathke’s
pouch (1). Somatotropes, which express growth hormone (GH),1
and lactotropes, which express prolactin (PRL), are thought to
be derived from a common precursor, the somatolactotrope
(2, 3).
The homeodomain transcription factor GHF-1/Pit-1 (4–6) is
required both for GH and prolactin PRL gene activation and for
emergence and expansion of both somatotropes and lactotropes
(7, 8). GHF-1 transcripts are detected several days before the
emergence of GH- or PRL-producing cells (9), suggesting the
existence of a precursor cell for the somatolactotropic lineage.
Using the 59 GHF-1 regulatory region to target the immortal-
izing oncoprotein SV40 T-antigen in transgenic mice has im-
mortalized this cell type. Mice expressing this transgene ex-
hibit dramatic dwarfism and develop pituitary tumors, which
express high levels of GHF-1 transcripts, low levels of GHF-1
protein, and no GH or PRL (10). This expression pattern is
consistent with that of GHF-1-expressing progenitors detected
between embryonic days 13 and 15 in the mouse (9). A cell
strain, designated GHFT, was established from these tumors.
GHFT cells continue to exhibit the same phenotype as the
original tumor and were therefore proposed to represent im-
mortalized somatotrope/lactotrope progenitor (10). Thus,
GHFT cells may constitute a convenient ex vivo system to study
the mechanism of cell differentiation in an endocrine gland
that itself is rather inaccessible to experimental manipulation
during embryogenesis.
The aim of this work was to identify factors that can induce
the lactotropic differentiation of this committed precursor and
explore their mechanism of action. Our efforts were focused on
those agents that are known to stimulate PRL gene expression
in differentiated lactotropes. Multiple hormones, growth fac-
tors, and oncogenes act in conjunction with GHF-1 to regulate
pituitary-specific expression of the PRL gene. Those factors
include ligands for nuclear hormone receptors (11, 12), hy-
pophysiotropic peptides that activate the protein kinase A or
protein kinase C pathways (13–16), or ligands of tyrosine ki-
nase growth factor receptors (17–20). Among the latter, the
family of fibroblast growth factors (FGFs) appears to play an
important role in pituitary organogenesis (21), in differentia-
tion of lactotropes (22), and recently in the dedifferentiation
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mechanism for lactotrope tumor pathogenesis (23). Particu-
larly, FGF-2 (or bFGF), which was originally isolated from the
pituitary gland (24–26), stimulates PRL secretion from normal
pituitary cells (27) and from pituitary adenomas (28). FGF-2
was recently found to stimulate the PRL promoter in the lac-
totropic GH4 cell line, and the functional components of the
signal transduction pathway activated by this growth factor
have been determined (29).
We report here that, among a variety of different agents
tested, only FGF-2 was able to initiate the PRL gene transcrip-
tion in GHFT cells. FGF-2 specifically stimulates PRL pro-
moter activity in transient transfection assays in GHFT cells.
The FGF-2 response element is located in the proximal pro-
moter sequences, and Ets transcription factors are required for
stimulation of the PRL promoter by FGF-2. GHFT cells express
low levels of Ets factors, which could contribute to the reduced
promoter responsiveness in these cells. In summary, our re-
sults indicate that FGF-2 is a strong up-regulator of PRL gene
expression in somatolactotropic progenitors and that this factor
is a strong candidate for a physiological inducer of lactotropic
differentiation in vivo and probably also in maintaining the
lactotropic phenotype of differentiated cells.
EXPERIMENTAL PROCEDURES
Cell Culture—GHFT cells were grown as described previously (10).
Experiments were performed in a defined serum-free (Dulbecco’s mod-
ified Eagle’s medium-high glucose) medium without phenol red, con-
taining insulin (10 mg/ml), sodium selenite (50 nM), human transferrin
(10 mg/ml), ascorbic acid (10 mg/ml), 0.1% bovine serum albumin (frac-
tion V), sodium pyruvate, glutamine, penicillin, and streptomycin. Cells
were maintained at least overnight in this defined medium before the
beginning of the experiments. GH4C1 and HeLa cells were grown in
Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum.
For the experiments, the cultures were shifted to medium containing
10% AG1X8 resin-charcoal-stripped newborn calf serum and 24 h later
shifted to serum-free medium. Treatments were administered in se-
rum-free medium.
Polymerase Chain Reaction after Reverse Transcription (RT-PCR)—
Total RNA was isolated from cells as described previously (30). One mg
of total RNA was used in RT-PCR reaction. The reverse transcription of
RNA to cDNA (using cloned murine leukemia virus reverse tran-
scriptase) and subsequent amplification (using GeneAmp® PCR process
and AmpliTaq® DNA polymerase) were performed all in a single reac-
tion tube to avoid cross-contamination after first strand synthesis. RNA
was copied to cDNA using random hexamers. To increase the specificity
and sensitivity of PCR amplification, the “hot start” technique was used
to suppress primer annealing to non-target sequences. AmpliWaxy
PCR Gem 100 (Perkin-Elmer) was added to each single reaction tube
containing a subset of amplification reagent for this proposal. For
amplification of PRL cDNA, the specific primers 59-CCCGAATACATC-
CTATCAAGAGCC-39 and 59-TTGATGGGCAATTTGGCACCTCAG-39
were used. These primers amplified a fragment of 263 bp. As an inter-
nal control, the amplified cDNA fragment spanned two spliced exons,
such that when genomic DNA was amplified the corresponding bands
were larger due to the presence of an intron.
RNase Protection Assay (RPA)—PRL mRNA was detected by RPA.
Total RNA from mouse pituitary was used as positive control. mRNA
from GHFT and HeLa cells was isolated by Oligotexy direct mRNA kit
(Qiagen). The mouse PRL cDNA was inserted into pGEM2, and after
XhoI linearization an antisense riboprobe was generated using SP6
RNA polymerase and [a-32P]UTP. The run-off transcription was al-
lowed to proceed for 60 min at 37 °C. The reaction was stopped by
digesting the DNA template with 10 units/ml DNase I for 15 min at
37 °C. The probe was purified from a polyacrylamide gel, eluted with
the RNAidy kit (Bio 101), and hybridization was performed overnight
at 50 °C. The hybridization solution contained 80% formamide, 40 mM
PIPES, pH 6.4, 1 mM EDTA, and 0.4 M NaCl. After hybridization,
samples were digested using RNase-ONEy (Promega; 50 units/sample,
50 min at 30 °C), precipitated with ethanol, and separated on a 6%
polyacrylamide, 8 M urea gel. Autoradiography of the RPA showed a
double protected fragment of 280 bp. Identical amounts of poly(A)1
RNA (16 mg) of each experimental group were used, except for total
mouse pituitary RNA, that served as a positive control, where 0.5 and
2 mg of total RNA were used.
mPRL Radioimmunoassay (RIA)—RIA for mouse PRL was per-
formed in duplicate as described previously (31). RIA components were
purchased to Dr. Parlow (Pituitary Hormones and Cancer Center, Har-
bor-UCLA Medical Center). Iodination of mPRL with 125I was con-
ducted using the chloramine-T method. Rabbit anti-mouse PRL serum
(anti-mPRL AFP-131078) was used at a final dilution of 1/200,000 and
samples were incubated for 18–24 h at room temperature prior to
addition of secondary antibody. Medium samples were compared with a
standard curve prepared with reference preparation (AFP-6476C), as
described previously (31). The assay sensitivity was 0.48 ng/ml. After 48
of incubation with or without FGF-2, culture media (8 ml) from GHFT
and HeLa cells were collected, frozen at 280 °C, lyophilized, and resus-
pended in 100 ml of phosphate buffer to load directly into the RIA.
Plasmids and Transient Transfections—Constructs containing dif-
ferent fragments of the rat PRL promoter fused to luciferase or chlor-
amphenicol acetyltransferase were described previously (12, 20, 33).
Expression vectors for GHF-1, c-Ets-1, dominant negative Ets-1 (encod-
ing the DNA binding domain of c-Ets-2), oncogenic Ha-rasVal-12, and the
dominant inhibitory Ha-rasAsn-17 mutant (20) were also used in the
transfection assays. Cells were transfected with calcium phosphate and
chloramphenicol acetyltransferase and luciferase activity determined
as described previously (12, 20). Reporter plasmids (1 mg/plate) were
transfected alone or in combination with the amounts of expression
vectors indicated in the corresponding figures. In all experiments the
amount of DNA was kept constant by addition of the same amount of an
“empty” expression vector.
Gel Retardation Assays—Assays were performed with nuclear ex-
tracts (32) from GHFT, GH4C1, and HeLa cells. The labeled PRL
promoter fragment 2176 to 2101 was obtained by PCR using the oli-
gonucleotides 59-cccaagcttTGGCCACTATGTCTTCCT-39 and 59-CAAT-
CATCTATTTCCGTCAT-39 as primers. The first oligonucleotide was
previously end-labeled with [32P]ATP using T4-polynucleotide kinase.
For the binding reaction, the extracts were incubated on ice for 15 min
in a buffer (20 mM Tris HCL (pH 7.5), 75 mM KCl, 1 mM dithiothreitol,
5 mg/ml bovine serum albumin, 13% glycerol) containing 3 mg of poly(dI-
dC) and then for 15–20 min at room temperature with approximately
50,000 cpm of labeled DNA fragment. DNA-protein complexes were
resolved on 6% polyacrylamide gels in 0.53 TBE buffer. The gels were
then dried and autoradiographed at 270 °C.
Western Blot Analysis—The levels of GHF-1 and Ets were deter-
mined by immunoblot analysis in GHFT, GH4C1, and HeLa cells. Cell
extracts were prepared in a lysis buffer supplemented with a mixture of
protease and phosphatase inhibitors (32). Equal amounts of proteins
(100 mg) were suspended in SDS sample buffer and resolved by 12%
SDS-polyacrylamide gel electrophoresis. The proteins were transferred
to a nitrocellulose membrane and, after blocking in 5% dried milk, were
probed with a 1/1000 dilution of rabbit polyclonal antibody generated
against GHF-1 (5), and with 1/500 dilution of an antibody (sc112, Santa
Cruz Biotechnology) that recognizes Ets-1 and Ets-2. Antigen-antibody
complexes were detected by chemiluminescence.
RESULTS
Screening for Factors That Induce PRL Expression in GHFT
Cells—To identify extracellular factors capable of inducing
PRL expression in GHFT precursor cells, we tested several
hormones, peptides, and growth factors known to have a stim-
ulatory effect on synthesis and/or release of PRL in differenti-
ated lactotropes. We arbitrarily divided the factors into 3
groups. In group I, we analyzed the effects of ligands of nuclear
hormone receptors that were demonstrated to transactivate the
GHF-1 and/or the PRL genes, including vitamin D3 (12, 33),
retinoic acid (34, 35), and both. 17b-Estradiol, a strong stimu-
lator of PRL gene expression, was tested alone and in combi-
nation with retinoic acid and/or vitamin D3. In group II, we
analyzed the peptides thyrotropin releasing hormone, epider-
mal growth factor, insulin, insulin-like growth factor-I, vaso-
active intestinal peptide, and pituitary adenylate cyclase acti-
vating polypeptide 1–38. We also checked combinations of two,
three, and four of these factors, along with combinations of
group I substances. Group III included human nerve growth
factor-b (NGF-b; Ref. 36) and FGF-2 (22), growth factors im-
plicated in differentiation of cultured neonatal pituitary cells.
We also checked these factors in combination with group I and
group II agents. All treatments were performed under the same
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conditions for at least 48 h. After treatment, total RNA was
isolated from cells, and expression of genes for PRL, GH, and
GHF-1 was examined by RT-PCR.
This screen revealed that only when FGF-2 was included in
the experimental treatment, expression of PRL mRNA was
detectable. None of the other agents either alone or in combi-
nation were able to induce PRL transcripts in GHFT cells (data
not shown). Fig. 1a shows a representative experiment of dose
response of FGF-2 effect on GHFT cells. The expected amplified
PRL band was obtained in cells treated with 10 nM FGF-2 for
24 h. This band was amplified when mouse pituitary RNA was
used as a positive control but not when HeLa cell RNA was
used as a negative control. Although 10 nM FGF-2 was the most
effective dose in inducing PRL gene expression, incubation
with 0.01 nM FGF-2 was sufficient to produce a weak detectable
signal. Expression of PRL mRNA was detectable within 6 h of
treatment with FGF-2 and remained elevated for at least 30 h
(Fig. 1b). The same treatment did not cause the appearance of
PRL mRNA in HeLa cells. Under all conditions at which FGF-2
induced PRL gene expression, no induction of GH gene expres-
sion was detectable. However, GHFT cells continued to express
GHF-1, a transcription factor necessary for GH and PRL gene
expression (data not shown).
Detection of PRL Transcripts by RNase Protection Assay—To
confirm that PRL gene expression was properly initiated after
FGF-2 treatment, RPA was used (Fig. 2a). The expected pro-
tected double fragment corresponding to properly initiated
PRL RNA was found in samples of FGF-treated GHFT cells
(lane 6) but not in the untreated cells (lane 5). Longer expo-
sures of the autoradiogram (up to 2 weeks) confirmed the
results, demonstrating the presence of the double protected
fragment of PRL mRNA only in the positive control (total RNA
from mouse pituitary) and in the newly differentiated precur-
sor (GHFT cells after FGF-2 exposure) (Fig. 2b). Therefore,
RPA confirmed that FGF-2 was able to promote PRL expres-
sion. However, the levels of PRL transcripts produced by
GHFT-treated cells were much lower than those expressed in
mouse pituitary (lanes 3 and 4). These results confirm that,
although FGF-2 appears to be an important factor for the
initiation of PRL gene expression in GHFT cells and is able to
initiate lactotrope differentiation, other factors are required to
attain the high levels of PRL gene transcription found in the
pituitary gland.
Detection of PRL Secretion—After mRNA production, the
next steps in expression of a polypeptidic hormone include
translation, post-translational processing and secretion to the
extracellular environment. Fig. 3 shows the effect of FGF-2 on
PRL secretion by GHFT cells. Immunoreactive PRL (IR-mPRL)
was essentially undetectable in medium from either untreated
GHFT cells or from HeLa cells treated for different time peri-
ods with FGF-2 (Fig. 3a). However, following FGF-2 treatment,
mPRL gradually accumulated in the culture medium and
reached a level of 2 ng/ml after 24 h of treatment. This stimu-
latory effect was not lost after longer incubation intervals (72
and 120 h). As shown in Fig. 3b, treatment with a low dose of
FGF-2 (0.1 nM) for 48 h was enough to produce detectable PRL
secretion. Detection of PRL in the cell culture supernatants
confirms that FGF-2 initiates differentiation of GHFT cells into
PRL-expressing and secreting lactotropic cells.
Induction of PRL Promoter Activity by FGF-2—To analyze
the elements that mediate increased PRL gene transcription in
response to FGF-2 treatment, transient transfection experi-
ments with reporter plasmids containing different fragments
(Fig. 4a) of the rat PRL promoter were performed. As shown in
Fig. 4b, incubation of GHFT cells with FGF-2 increased the
activity of a promoter construct which contains the PRL distal
enhancer (between 21.8 and 1.5 kilobase pairs) ligated to the
2422/134 PRL promoter fragment. In five independent exper-
iments, incubation for 8–9 h with 1 nM FGF-2 increased lucif-
erase activity by 2.7 6 0.3-fold (p , 0.001). A 24-h incubation
stimulated activity by 1.9 6 0.2 (p , 0.01). A construct extend-
ing only to 2422 bp, which does not contain the distal en-
hancer, was also stimulated by FGF-2 (Fig. 4b). In contrast, a
plasmid in which the 278/134 promoter fragment was ligated
to the distal enhancer was not significantly activated by FGF-2.
The activity of the 238/134 fragment was very low and was not
affected by FGF-2. These data demonstrate that the elements
responsible for FGF-2 responsiveness are contained between
nucleotides 2422 and 278. These results are in agreement
with the previous observation that FGF-2 induction of the PRL
promoter in GH4 cells maps to this region. A more detailed
mapping was performed with plasmids extending to 2176,
2101, and 270 bp, and to better resolve the effect of FGF-2 the
transfections were performed in GH4C1 cells, in which incuba-
tion with FGF-2 produced a stronger stimulation of PRL pro-
moter activity (Fig. 4c). A similar increase (9-fold) was found
with constructs containing either the entire 59-flanking region
(3 kilobase pairs) or extending only to 2176 bp. However,
stimulation decreased to a mere 2-fold when sequences be-
tween 2176 and 2101 were deleted, and disappeared upon a
deletion to 270. Thus, the region between 2176 and 2101 bp of
the PRL promoter, which contains a GHF-1 binding site over-
lapping with an Ets binding site (37, 38), significantly contrib-
utes to the induction of promoter activity by FGF-2. The role of
the proximal Ets binding sites in the residual stimulation by
FGF-2 of the reporter that extents 2101 bp is demonstrated by
FIG. 1. FGF-2 induces PRL gene expression in GHFT cells. a, representative experiment of FGF-2 dose response on PRL gene expression
in GHFT cells. GHFT and HeLa cells were treated for 24 h with the indicated concentrations of FGF-2, RNA was extracted, and RT-PCR performed.
The band corresponding to the correct length PRL mRNA-derived product is indicated. Appearance of a larger band indicates DNA contamination.
Lanes 1–4, GHFT cells treated with 0, 1 3 1028, 1 3 10–11, and 1 3 10–13 M FGF-2, respectively. Lanes 5–8, HeLa cells with the same treatments.
Lane 9, RNA from mouse pituitary (used as a positive control). b, representative experiment of FGF-2 time-course on PRL gene expression in GHFT
cells. Cells were treated with 10 nM FGF-2 for the time periods indicated or with an equal volume of vehicle (lanes 1–6). As a negative control, HeLa
cells were also incubated in the presence of absence of 10 nM FGF-2 for 30 h (lanes 7 and 8). Lane 9, RNA from mouse pituitary.
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the finding that the 2101mut reporter in which the Ets binding
sites were rendered non-functional (20) did not show a signif-
icant response to FGF-2 (Fig. 4c).
Role of GHF-1, Ets, and Ras in PRL Promoter Stimulation by
FGF-2—In different experiments, basal PRL promoter activity
was found to be consistently lower in precursor GHFT cells
than in the PRL-producing GH4C1 cells. As both GHF-1 and
Ets factors appear to play an important role in PRL gene
transcription, we tested the possibility that a lower expression
of these transcription factors in the precursor cells could con-
tribute to low promoter activity. Indeed, as analyzed by gel
retardation assay with the prolactin promoter fragment 2176
to 2101, GHFT cells expressed lower levels of GHF-1 than
GH4C1 cells (Fig. 5a). GHF-1 and Ets protein levels were then
compared by Western blotting of GHFT, GH4C1, and HeLa cell
extracts. This analysis confirmed the reduced content of GHF-1
in GHFT cells. The anti-GHF-1 antibody recognized the char-
acteristic 31- and 33-kDa doublet in pituitary cells, which was
less abundant in GHFT cells (Fig. 5b). In the blot shown in the
figure, obtained after a long exposure, two other weaker bands
of 36 and 28 kDa were observed in GH4C1 cells, and no bands
were detected in HeLa cells. In addition, the levels of endoge-
nous Ets factors were markedly lower in GHFT cells than in
GH4C1 or HeLa cells (Fig. 5b). To functionally determine the
role of these factors in basal PRL promoter activity as well as
in its induction by FGF-2, we examined the influence of ectopi-
cally expressed c-Ets-1 alone or in combination with GHF-1 on
PRL promoter activity. Overexpression of GHF-1 and/or
c-Ets-1 did not further activate the PRL promoter in GH4C1
cells that already contain high endogenous levels of these fac-
tors (20). However, cotransfection with the c-Ets-1 vector in-
creased the activity of the PRL promoter in GHFT cells and
overexpression of GHF-1 further enhanced this activation (Fig.
5c). After overexpression of c-Ets-1 and GHF-1, PRL promoter
activity in GHFT cells was quite similar to that found in
GH4C1 cells. These results suggest that the endogenous levels
of GHF-1 and Ets factors are limiting in GHFT cells and con-
firm the important role of Ets proteins in activation of this
promoter.
Ras acts synergistically with Ets and GHF-1 to stimulate
PRL promoter activity in lactotropic cell lines (20, 37, 38). An
impaired Ras activation, which is a strong stimulator of PRL
promoter activity (37), may be responsible for the decreased
FGF-2 responsiveness of GHFT cells. However, coexpression of
FIG. 2. RNase protection assay of
PRL mRNA. Autoradiograms of a RNase
protection assay with RNA from mouse
pituitary, GHFT cells, and HeLa cells.
The left panel shows the autoradiogram
after overnight exposure, and the right
panel shows lanes 5–8 of the same auto-
radiogram after a 10-day exposure. Lane
1, size markers; lane 2, undigested PRL
probe; lanes 3 and 4, RNA from mouse
pituitary (2 and 0.5 mg of total RNA, re-
spectively); lane 5, RNA from untreated
GHFT cells; lane 6, RNA from GHFT cells
after exposure to 10 nM FGF-2 for 48 h;
lane 7, RNA from untreated HeLa cells;
lane 8, RNA from HeLa cells treated with
10 nM FGF-2, used again as a negative
control. Poly(A)1 RNA (16 mg) from GHFT
and HeLa cells was used in the assays. A
double protected fragment of PRL mRNA
indicated by an arrow is detected in lane 6
(GHFT cells treated with FGF-2) and in
lanes 3 and 4 (mouse pituitary RNA
loaded as a positive control). All other
lanes are negative even after long expo-
sure times.
FIG. 3. Effect of FGF-2 treatment on
PRL release in GHFT cells. a, IR-
mPRL was determined in the culture me-
dia of GHFT and HeLa cells after expo-
sure to FGF-2 (10 nM) for 2, 6, 12, 24, 72,
and 120 h. A representative experiment
out of three is shown. b, accumulation of
IR-mPRL was analyzed in media from
HeLa cells and from GHFT cells treated
for 48 h with 0, 0.1, and 10 nM FGF-2. The
data shown are the mean 6 S.D. obtained
from five independent cultures.
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constitutively active RasVal-12 in GHFT cells potentiated PRL
promoter activity by more than 100-fold in cells cotransfected
with c-Ets-1 and GHF-1 (Fig. 5d).
Ets factors are targets for FGF-activated Ras-dependent sig-
nal transduction pathway responsible for PRL promoter acti-
vation in GH4 cells (29). To analyze the role of endogenous Ets
FIG. 4. FGF-2 activates the PRL pro-
moter. a, schematic structure of the 59-
flanking region of the PRL promoter de-
picting the positions of the GHF-1 binding
sites in the proximal promoter (1P–4P)
and the distal enhancer (1D–4D). The po-
sitions of the Ets binding sites in the prox-
imal promoter are also shown. In the
lower panels transient transfection exper-
iments were performed in GHFT cells (b)
and GH4C1 cells (c) treated with 1 nM
FGF-2 for 9 h. The plasmids used, con-
taining different PRL promoter frag-
ments, are indicated in the ordinates. Re-
sults are expressed as -fold activation
relative to the full-length promoter activ-
ity, and each data point represents the
mean 6 S.D. obtained from four inde-
pendent cultures. Similar results were ob-
tained in two additional experiments.
FIG. 5. GHF-1 and Ets factors in
GHFT cells. a, gel retardation assays
with extracts from HeLa, GH4C1, and
GHFT cells and a labeled PRL promoter
fragment containing sequences from
2176 to 2101. b, protein extracts were
subjected to Western blot analysis with
antibodies against Ets factors (upper
panel) and GHF-1 (lower panel). In vitro
translated c-Ets-1 (5 ml) was used as a
control with the anti-Ets antibody. c,
GHFT cells were cotransfected with the
PRL promoter construct containing the
distal enhancer ligated to sequences
2422/134 and expression vector encoding
GHF-1 (0.4 mg) and or c-Ets-1 (0.5 mg).
Cells were incubated for 24 h in the pres-
ence and absence of 10 nM FGF-2 and
luciferase activity determined. Reporter
activity was determined in parallel in
GH4C1 cells after the same treatment. d,
luciferase activity was measured in
GHFT cells cotransfected 24 h before with
the reporter plasmid and expression vec-
tors for c-Ets-1, GHF-1, and/or the onco-
genic RasVal-12 mutant (5 mg). All trans-
fection data shown are the mean 6 S.D.
obtained from triplicate cultures. A repre-
sentative experiment out of three is
shown.
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transcription factors in FGF-2-induced PRL gene expression in
GHFT cells, the influence of expression of the DNA-binding
domain of c-Ets-2, which results in a dominant negative effect,
was examined. Overexpression of the ETS domain significantly
reduced the induction of PRL promoter activity by FGF-2 in
both GHFT and GH4C1 cells (Fig. 6a). These results confirm
the involvement of Ets-proteins in FGF-2-induced PRL gene
transcription.
Ets proteins, which mediate transcriptional responses to mi-
togen-activated protein kinases (MAPK), are an important el-
ement in PRL promoter stimulation by growth factors, which
cause Ras activation (39). However, it was described that
FGF-2 induction of PRL promoter activity was independent of
Ras in GH4 cells (29). We therefore examined the effect of the
dominant negative RasAsn-17 mutant on PRL promoter activa-
tion by FGF-2 in GHFT and GH4C1 cells. Expression of the
dominant negative Ras reduced the response to FGF-2 not only
in GHFT cells, but also in GH4C1 cells (Fig. 6a). However, a
partial response to FGF-2 was still found. This suggests that
stimulation of the PRL promoter by FGF-2 is at least partially
Ras-dependent. Therefore, although Ras and Ets appear to be
required for a full FGF-2 responsiveness, activation of addi-
tional pathways is also important. This prompted us to inves-
tigate whether the phosphoinositol 3-kinase signaling path-
way, which contributes to PRL promoter induction by insulin-
like growth factor-I in GH4C1 cells (20), could also be involved
in the stimulatory effect of FGF-2. Incubation of GHFT or
GH4C1 cells with wortmannin, a specific inhibitor of phosphoi-
nositol 3-kinase, had little if any effect on induction of the PRL
promoter by FGF-2 (Fig. 6a). Therefore, this signaling pathway
does not appear to be required for induction of PRL gene
expression by FGF-2. On the other hand, as illustrated in Fig.
6b, expression of oncogenic RasVal-12 mimicked the effect of
FGF-2 and caused marked PRL promoter activation in both cell
types. Under these conditions in which the Ras signaling path-
way is maximally activated, treatment with FGF-2 did not
produce further stimulation.
DISCUSSION
Lactotropes are post-mitotic cells whose principal function is
the synthesis and secretion of PRL. During development, the
hierarchy of regulatory events that leads to generation of lac-
totropes remains to be elucidated. Immortalization of neuroen-
docrine cells at specific stages of differentiation by targeted
oncogenesis has been successfully used to establish clonal cell
lines representing different steps in a developmental cell line-
age (10, 39, 40). In this work we show that FGF-2 initiates PRL
gene transcription and PRL secretion in GHFT cells, suggest-
FIG. 6. Role of endogenous Ets fac-
tors, Ras, and phosphoinositol 3-ki-
nase on the FGF-2 response. a, GHFT
(left panel) or GH4C1 cells (right panel)
were transfected with the same reporter
construct as in Fig. 5c and 4 mg of expres-
sion vectors encoding dominant negative
(DN) mutants of Ras or Ets. The cells
were treated for 8 h with 1 nM FGF-2.
When indicated, the cells were preincu-
bated for 30 min with 100 nM wortmannin
before the addition of the growth factor. b,
GHFT and GH4C1 cells were transfected
with the PRL promoter construct and 1
mg of RasVal-12. Luciferase activity was
determined in cells incubated in the pres-
ence and absence of FGF-2. In both pan-
els, data are expressed relative to the val-
ues obtained in the corresponding
untreated cells transfected with the re-
porter plasmid alone. Each data point
represents the mean 6 S.D. obtained
from triplicate cultures, and similar re-
sults were obtained in an additional
experiment.
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ing that this growth and differentiation factor could play a role
in the generation of the lactotropic phenotype. These findings
also suggest that GHFT cells can be used as a model system to
analyze the progression from the committed somatolactotrope
cell precursor to the terminally differentiated PRL-expressing
cell.
The effect of FGF-2 on the somatolactotrope precursor is not
surprising in view of previous observations of the effect of FGF
family members on PRL gene expression. For instance, FGF-2
and FGF-4 are abundant in human pituitary tumors, can stim-
ulate PRL secretion from cultured pituitary adenomas, and
may even be involved in the development and progression of
these tumors (23, 28). Indeed, recent data have demonstrated
the early involvement of FGF-2 in prolactinoma pathogenesis
(41).
In the rat pituitary tumor cell lines GH3 and GH4, it has
been shown that FGFs increase PRL mRNA (42, 43) and PRL
promoter activity in transient transfection assays (29, 42). Our
data confirm these observations and demonstrate that PRL
transcription is initiated by FGF-2 in GHFT cells, which prior
to that treatment do not produce any PRL. Therefore, by in-
ducing PRL expression and secretion, the hallmarks of lacto-
tropes, FGF-2 converts these murine somatolactotropic progen-
itors into early lactotropic precursors. The level of PRL
expression after FGF-2 exposure in GHFT cells was low but
specific and with physiological significance because the doses
capable to induce lactotropic differentiation are within the
calculated Kd of cellular binding sites for FGF-2 (44, 45). The
stimulatory effect of FGF-2 caused not only PRL gene tran-
scription but also hormonal synthesis and secretion. Conver-
sion of these precursor cells into fully differentiated lactotropes
that express high levels of PRL will probably require additional
factors that remain to be identified. As the anterior pituitary is
composed of a complex network of endocrine and non-endocrine
cells, which undoubtedly cooperate to assist each other devel-
opment, a complete lactotrope development most likely re-
quires endocrine, paracrine, and autocrine mechanisms, which
are not present in a single cell population such as GHFT cells.
In contrast to FGF-2, other agents that have a strong stim-
ulatory action on PRL gene expression in differentiated lacto-
tropes were unable to induce PRL gene transcription in GHFT
cells. In agreement with our results, incubation of newborn
rat anterior pituitary cells with FGF, but not with other
hypophysiotropic peptides, increases significantly the percent-
age of PRL-producing cells (22). Therefore, in different mam-
malian species, FGF factors appear to play a role in differen-
tiation and function of lactotropes. It is particularly interesting
that NGF did not elicit PRL gene expression in GHFT cells,
because this factor is able to support the proliferation and
differentiation of lactotropes in cultures of pituitary cells pre-
pared from early postnatal rats (36). Our findings suggest that
NGF could modulate PRL expression only in differentiated
lactotropes, after FGF-2 has triggered the differentiation proc-
ess. This also occurs during differentiation of cells of the sym-
pathoadrenal lineage, in which FGF-2 initiates differentiation
and NGF promotes further maturation and survival (46).
Although FGF-2 is able to cause PRL gene transcription in
GHFT cells, the induced level of PRL transcripts is low. An
appropriate threshold or constellation of transcription factors
required for full activation of the PRL promoter may be lacking
in GHFT cells, thereby explaining the low level of PRL gene
transcription. The proximal region of the PRL gene is sufficient
to mediate transcriptional responses to several hormones in
mature lactotropes, and this region contains several binding
sites for the pituitary specific transcription factor GHF-1, as
well as for Ets factors. Gel retardation experiments with the
2176/2101 PRL promoter fragment demonstrated that indeed
the concentration of nuclear factors that bind to these se-
quences is significantly lower in GHFT cells than in the differ-
entiated cell line GH4C1. The most abundant factor that binds
to these sequences is GHF-1, and our results show that GHFT
cells express less GHF-1 protein than GH4C1 cells do. Further-
more, we have also observed that the levels of Ets factors,
which also play a major role on PRL gene transcription (47), are
markedly lower in GHFT cells. That both types of transcription
factors are present in limiting concentrations in GHFT cells is
functionally proved by the finding that elevated expression of
GHF-1 or c-Ets-1 causes a marked increase in PRL promoter
activity. By contrast, overexpression of GHF-1 or Ets-1 in dif-
ferentiated GH4C1 cells, where the amounts of endogenous
factors are sufficient for maximal stimulation of PRL promoter
activity, does not result in further PRL transcription.
In keeping with previous observations (29), we have mapped
the FGF responsiveness of the PRL promoter in GHFT cells to
sequences containing Ets binding sites. Furthermore, our re-
sults demonstrate that endogenous Ets factors are the nuclear
targets for the FGF-2 signal transduction pathway. Since Ets
factors have also been established as nuclear acceptors for the
Ras-MAPK pathway (42) and FGFs activate this signaling
pathway, induction of lactotrope differentiation of GHFT cells
by FGF-2 is likely to involve the Ras-MAPK signaling pathway
as well. However, it had been reported that FGF-mediated
induction of the PRL promoter in GH4 cells was not mediated
via Ras but was dependent on MAPK (29). Our data do not
confirm these observations in GHFT cells, as expression of a
dominant negative Ras mutant was able to reduce PRL pro-
moter activation. It is possible that FGF-2 could activate the
promoter via a Ras-dependent pathway in the precursor cells,
but that after terminal lactotrope differentiation it relies on a
Ras-independent pathway. Nevertheless, this is unlikely since
the dominant-negative Ras mutant had a similar inhibitory
effect on the FGF-2 response also in GH4C1 cells. On the other
hand, our results also show that the dominant inhibitory Ras
blocks only partially the FGF-2 response. Taken together our
results suggest that activation of the Ras pathway leading to
phosphorylation of an Ets factor mediates, at least part of the
PRL induction by FGF-2, but other, still unidentified, Ras-
independent pathway(s) also contribute to this response.
In summary, differentiation of GHFT cells can be induced by
FGF-2 through an, at least in part, Ras-dependent pathway
where GHF-1 and Ets are limiting factors. Therefore, FGF-2 is
a strong candidate for initiating the processes of lactotrope cell
differentiation in vivo and, probably, also for maintaining the
normal lactotrope phenotype of differentiated cells. Undoubt-
edly, other still unknown factors should act in concert with
FGF-2, either simultaneously or sequentially, to induce a fully
differentiated lactotrope phenotype. The availability of immor-
talized lactotrope progenitors has provided an invaluable tool
for analysis of the mechanisms of developmental regulation of
PRL gene expression. Further investigation with this model
might be also useful for defining the signaling system that
controls growth and dedifferentiation of an inaccessible central
endocrine gland in which the more frequent tumors are the
lactotrope adenomas. However, caution is necessary to extrap-
olate the results obtained in a SV40-transformed cell line de-
rived from a pituitary tumor to the in vivo mechanisms of
lactotrope development.
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